Acquisition provides growth opportunities and increases synergies within the ProScan Family of Companies
ProScan Imaging, one an international radiology services group, has increased its majority ownership of WorldCare Clinical (WCC) LLC to 100 percent, aiming to position the organization for growth and increased synergies in technology, service offerings, expertise, and accredited educational programs to benefit their biopharmaceutical and device manufacturer customers.
“The acquisition allows us to more closely align WCC’s exceptional trial management and assessment accuracy and consistency testing methodology with ProScan’s world-wide medical image file exchange platform and its international teleradiology assets,” stated Michael O’Brien, President and COO of the ProScan Family of Companies. “The enhanced service delivery model will allow WCC’s customers to lower their trial costs, while flexibly accessing the most appropriate independent expert assessment team.”
“Our access to large groups of sub-specialty trained, practicing radiologists and clinicians at ProScan and Harvard teaching hospitals coupled with our rapid turnaround global teleradiology and telemedicine endpoint assessment committees (EACs), all uniquely position us to take advantage of the ever changing and more rigorous clinical trial requirements,” stated Dr. Richard Walovitch, President of WCC. “As the number of stakeholders involved in product life cycle management increases, WCC can provide continuity and efficiency of service, effective efficacy and safety evaluation, reporting, and continuing medical education, informing these stakeholders on the best path for their product from early clinical trial activity through commercialization.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.